For decades, the standard neoadjuvant therapy regimen for locally advanced rectal cancer consisted of chemoradiation, surgical resection, and consideration of adjuvant systemic therapy. Additional data have emerged suggesting neoadjuvant systemic therapy as a reasonable alternative to chemoradiation in selected patients. In addition, a total neoadjuvant therapy approach integrating both chemotherapy and chemoradiation results in superior cancer outcomes and the potential for consideration of nonoperative management in patients with a clinical complete response. Despite a multitude of therapeutic pathways for the management of rectal cancer, what is clear, however, is the importance of a multidisciplinary approach with shared patient and provider decision-making.
Keyphrases
- rectal cancer
- locally advanced
- squamous cell carcinoma
- radiation therapy
- decision making
- end stage renal disease
- early stage
- newly diagnosed
- primary care
- ejection fraction
- mesenchymal stem cells
- prognostic factors
- stem cells
- patients undergoing
- peritoneal dialysis
- papillary thyroid
- deep learning
- quality improvement
- skeletal muscle
- insulin resistance
- replacement therapy